Купить (150 RUB)
|сгенерировать QR код
Открытый доступ
Доступ платный или только для Подписчиков
Кардиотоксичность ингибиторов контрольных точек: фокус на иммунных побочных эффектах
https://doi.org/10.33667/2078-5631-2024-7-26-33
Аннотация
Показания к применению ингибиторов контрольных точек при онкологических заболеваниях продолжает расширяться в ближайшие годы, что является перспективным направлением для будущих клинических исследований. Однако диагностика иммунных побочных эффектов является сложной задачей из-за его гетерогенных клинических проявлений, которые варьируются от субклинического течения до молниеносных проявлений с высокой госпитальной летальностью. Потенциальным механизмом может быть пролиферация и клональная экспансия Т-лимфоцитами антигенов в опухолевых клетках и пораженных собственных тканях. Точный патофизиологический механизм остается неясным, а профиль риска пациентов, столкнувшихся с кардиотоксичностью, неизвестен. Продолжающиеся интенсивные усилия исследовательских сообществ и междисциплинарное сотрудничество в области онкологии и кардиологии помогут решить эти проблемы и тем самым позволят иммунотерапии достичь максимального потенциального эффекта в лечении онкологических заболеваний.
Об авторах
Ю. И. Бузиашвили
ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева»
Россия
Россия
Бузиашвили Юрий Иосифович - д.м.н., профессор, академик РАН, зав. клинико-диагностическим отделением
Москва
Э. У. Асымбекова
ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева»
Россия
Россия
Асымбекова Эльмира Уметовна - д.м.н., в.н.с. клинико-диагностического отделения
Москва
Э. Ф. Тугеева
ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева»
Россия
Россия
Тугеева Эльвина Фаатовна - д.м.н., с.н.с. клинико-диагностического отделения
Москва
Е. В. Артамонова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина»
Россия
Россия
Артамонова Елена Владимировна - д.м.н., в.н.с. отделения изучения новых противоопухолевых лекарств
Москва
Ф. Р. Акилджонов
ФГБУ «Национальный медицинский исследовательский центр сердечно-сосудистой хирургии им. А.Н. Бакулева»
Россия
Россия
Акилджонов Фирдавсджон Рустамджонович - аспирант клинико-диагностического отделения
Москва
Список литературы
1. Xiang Y, Gong M, Deng Y, Wang H, Ye D. T cell effects and mechanisms in immunotherapy of head and neck tumors. Cell Commun Signal. 2023;21(1):49. Published 2023 Mar 5. doi:10.1186/s12964–023–01070-y
2. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi:10.1097/COC.0000000000000239
3. L’Orphelin JM, Varey E, Khammari A, Dreno B, Dompmartin A. Severe Late-Onset Grade III–IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. Cancers (Basel). 2021;13(19):4928. Published 2021 Sep 30. doi:10.3390/ cancers13194928
4. L’Orphelin JM, Dollalille C, Akroun J, Alexandre J, Dompmartin A. Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma. Cancers (Basel). 2023;15(7):2170. Published 2023 Apr 6. doi:10.3390/cancers15072170
5. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combi-nation Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–1755. doi:10.1056/NEJMoa1609214
6. Frascaro F, Bianchi N, Sanguettoli F, et al. Immune Checkpoint Inhibitors-Asso-ciated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J Clin Med. 2023;12(24):7737. Published 2023 Dec 17. doi:10.3390/jcm12247737
7. Bi H, Ren D, Wang Q, Ding X, Wang H. Immune checkpoint inhibitor-induced myo-carditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Ann Palliat Med. 2021;10(1):793–802. doi:10.21037/apm-20–2449
8. Wong CK, Lam TH, Liao SY, Lau YM, Tse HF, So BYF. Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. Biomedicines. 2023;11(1):107. Published 2023 Jan 1. doi:10.3390/biomedicines11010107
9. Chiang CH, Chiang CH, Ma KS, et al. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn J Clin Oncol. 2022;52(12):1389–1398. doi:10.1093/jjco/hyac150
10. Ball S, Ghosh RK, Wongsaengsak S, et al. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week [published correction appears in J Am Coll Cardiol. 2019 Nov 26;74(21):2711–2712]. J Am Coll Cardiol. 2019;74(13):1714–1727. doi:10.1016/j.jacc.2019.07.079
11. Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25(5):818–830. doi:10.1007/s10147–019–01548–1
12. Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29(5):3044–3060. Published 2022 Apr 24. doi:10.3390/curroncol29050247
13. Savoia P, Astrua C, Fava P. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother. 2016;12(5):1092–1101. doi:10.1080/21645515.2015.1129478
14. Ventola CL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T. 2017;42(8):514–521.
15. Eno J. Immunotherapy Through the Years. J Adv Pract Oncol. 2017;8(7):747–753.
16. Pan C, Liu H, Robins E, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):29. Published 2020 Apr 3. doi:10.1186/s13045–020–00862-w
17. Parvez A, Choudhary F, Mudgal P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Im-munol. 2023;14:1296341. Published 2023 Dec 1. doi:10.3389/fimmu.2023.1296341
18. Xu Y, Wan B, Chen X, et al. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019;8(4):413–428. doi:10.21037/tlcr.2019.08.09
19. Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol. 2023;29(6):1054–1075. doi:10.3748/wjg.v29.i6.1054
20. Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers (Basel). 2023;15(4):1106. Published 2023 Feb 9. doi:10.3390/cancers15041106
21. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: un-derstanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423–020–0488–6
22. Eskandari-Malayeri F, Rezaei M. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Front Immunol. 2022;13:996145. Published 2022 Oct 5. doi:10.3389/fimmu.2022.996145
23. Huang Q, Zheng Y, Gao Z, Yuan L, Sun Y, Chen H. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. J Cancer. 2021;12(4):1133–1143. Published 2021 Jan 1. doi:10.7150/jca.49325
24. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014;20(4):265–271. doi:10.1097/PPO.0000000000000059
25. Paucek RD, Baltimore D, Li G. The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends Immunol. 2019;40(4):292–309. doi:10.1016/j.it.2019.02.002
26. Liu H, Zhao Y, Xie A, et al. Interleukin-1β, Oxidative Stress, and Abnormal Calcium Handling Mediate Diabetic Arrhythmic Risk. JACC Basic Transl Sci. 2021;6(1):42–52. Published 2021 Jan 20. doi:10.1016/j.jacbts.2020.11.002
27. Cone EB, Haeuser L, Reese SW, et al. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS One. 2022;17(11): e0272022. Published 2022 Nov 1. doi:10.1371/journal.pone.0272022
28. Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel). 2021;13(20):5218. Published 2021 Oct 18. doi:10.3390/cancers13205218
29. Minotti G, Menna P, Camilli M, Salvatorelli E, Levi R. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Adv Pharmacol. 2022;94:365–409. doi:10.1016/bs.apha.2022.02.002
30. Dal’bo N, Patel R, Parikh R, et al. Cardiotoxicity of Contemporary Anticancer Immunotherapy. Curr Treat Options Cardiovasc Med. 2020;22(12):62. doi:10.1007/s11936–020–00867–1
31. Baik AH, Oluwole OO, Johnson DB, et al. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021;128(11):1780–1801. doi:10.1161/CIRCRESAHA.120.315894
32. Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular Risks Associated with Gender and Aging. J Cardiovasc Dev Dis. 2019;6(2):19. Published 2019 Apr 27. doi:10.3390/jcdd6020019
33. Waheed N, Fradley MG, DeRemer DL, et al. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021;7(1):10. Published 2021 Mar 18. doi:10.1186/s40959–021–00097–9
34. Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol. 2022;13:835510. Published 2022 Apr 19. doi:10.3389/fphar.2022.835510
35. Ito T, Kaku-Ito Y, Ohno F, Nakahara T. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan. Front Med (Lausanne). 2023;10:1293397. Published 2023 Dec 7. doi:10.3389/fmed.2023.1293397
36. Chitturi KR, Xu J, Araujo-Gutierrez R, et al. Immune Checkpoint Inhibitor-Re-lated Adverse Cardiovascular Events in Patients With Lung Cancer. JACC CardioOncol. 2019;1(2):182–192. Published 2019 Dec 17. doi:10.1016/j.jac-cao.2019.11.013
37. Zhao F, Shen D, Shang M, et al. Immunotherapy: A new target for cancer cure (Review). Oncol Rep. 2023;49(5):100. doi:10.3892/or.2023.8537
38. Cathcart-Rake EJ, Sangaralingham LR, Henk HJ, Shah ND, Riaz IB, Mansfield AS. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. Clin Lung Cancer. 2020;21(5):421–427.e2. doi:10.1016/j.cllc.2020.04.003
39. Thavendiranathan P, Zhang L, Zafar A, et al. Myocardial T1 and T2 Mapping by Mag-netic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myo-carditis. J Am Coll Cardiol. 2021;77(12):1503–1516. doi:10.1016/j.jacc.2021.01.050
40. Zotova L. Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Re-ported Clinical Cases. Diagnostics (Basel). 2023;13(7):1243. Published 2023 Mar 25. doi:10.3390/diagnostics13071243
41. Bockstahler M, Fischer A, Goetzke CC, et al. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immuno-proteasome Inhibitor and Genetic Ablation. Circulation. 2020;141(23):1885–1902. doi:10.1161/CIRCULATIONAHA.119.043171
42. Trontzas IP, Vathiotis IA, Kyriakoulis KG, et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel). 2023;15(9):2637. Published 2023 May 6. doi:10.3390/cancers15092637
43. Verbeek JS, Hirose S, Nishimura H. The Complex Association of FcγRIIb With Autoimmune Susceptibility. Front Immunol. 2019;10:2061. Published 2019 Oct 15. doi:10.3389/fimmu.2019.02061
44. Miyabe C, Dong Y, Ikeda T, Takahashi K, Miyabe Y, Kawakami T. Immune check-point molecule expression is altered in the skin and peripheral blood in vasculitis. Sci Rep. 2021;11(1):20019. Published 2021 Oct 8. doi:10.1038/s41598–021–99558–5
45. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-on-cology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in Eur Heart J. 2023 May 7;44(18):1621]. Eur Heart J. 2022;43(41):4229–4361. doi:10.1093/eurheartj/ehac244
46. Teymouri N, Mesbah S, Navabian SMH, et al. ECG frequency changes in po-tassium disorders: a narrative review. Am J Cardiovasc Dis. 2022;12(3):112–124. Published 2022 Jun 15.
47. Ganesh S, Zhong P, Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treat-ment. Front Cardiovasc Med. 2022;9:997660. Published 2022 Sep 20. doi:10.3389/ fcvm.2022.997660
48. Zhao Y, Lyu N, Zhang W, Tan H, Jin Q, Dang A. Prognosis Implication of N-Terminal Pro-B-Type Natriuretic Peptide in Adult Patients With Acute Myocarditis. Front Car-diovasc Med. 2022;9:839763. Published 2022 Mar 30. doi:10.3389/fcvm.2022.839763
49. Laufer-Perl M, Gilon D, Kapusta L, Iakobishvili Z. The Role of Speckle Strain Echocardiography in the Diagnosis of Early Subclinical Cardiac Injury in Cancer Patients-Is There More Than Just Left Ventricle Global Longitudinal Strain?. J Clin Med. 2021;10(1):154. Published 2021 Jan 5. doi:10.3390/jcm10010154
50. Cadour F, Cautela J, Rapacchi S, et al. Cardiac MRI Features and Prognos-tic Value in Immune Checkpoint Inhibitor-induced Myocarditis. Radiology. 2022;303(3):512–521. doi:10.1148/radiol.211765
51. Ammirati E, Buono A, Moroni F, et al. State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. Curr Cardiol Rep. 2022;24(5):597–609. doi:10.1007/s11886–022–01680-x
52. Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Ther-apeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-On-cology. Circulation. 2019;140(2):80–91. doi:10.1161/CIRCULATIONAHA.118.034497
53. Bai X, Hu J, Betof Warner A, et al. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021;27(21):5993–6000. doi:10.1158/1078–0432.CCR-21–1283
54. Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept [published correction appears in J Immunother Cancer. 2022 May;10(5):]. J Immunother Cancer. 2022;10(4): e004699. doi:10.1136/jitc-2022–004699
55. Wang A, Xu Y, Fei Y, Wang M. The role of immunosuppressive agents in the man-agement of severe and refractory immune-related adverse events. Asia Pac J Clin Oncol. 2020;16(4):201–210. doi:10.1111/ajco.13332
Рецензия
Для цитирования:
Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф., Артамонова Е.В., Акилджонов Ф.Р. Кардиотоксичность ингибиторов контрольных точек: фокус на иммунных побочных эффектах. Медицинский алфавит. 2024;(7):26-33. https://doi.org/10.33667/2078-5631-2024-7-26-33
For citation:
Buziashvili J.I., Asymbekova E.U., Tugeeva E.F., Artamonova E.V., Akildzhonov F.R. Cardiotoxicity of checkpoint inhibitors: focus on immune side effects. Medical alphabet. 2024;(7):26-33. (In Russ.) https://doi.org/10.33667/2078-5631-2024-7-26-33
Просмотров:
223
Послать статью по эл. почте 